A look at five ASX multibagger healthcare stocks

Highlights 

  • The Australian healthcare industry is grabbing attention on the back of increasing incidence of severe diseases and increasing aging demographics.
  • Some ASX-listed healthcare shares never fail to cheer up their investor by providing significant returns over time.
  • Actinogen Medical, Imugene, and Prescient Therapeutics have delivered exceptional YTD returns, followed by Incannex Healthcare and MGC Pharmaceuticals.

This year, the ASX healthcare index gained a little more than 10% year to date. The healthcare index acts as a benchmark for investors, reflecting performance of healthcare players who are part of the ASX healthcare index.

The Australian healthcare sector comprises hospitals, pharmaceuticals, biotechnology, medical devices, telemedicine, health insurance, and medical equipment. Besides, the healthcare industry prospects are backed by increasing prevalence of severe diseases and the rise in aging demographics. Healthcare shares rarely fail to cheer their investors and provide consistent returns over time.

In the meantime, some ASX-listed healthcare shares have already proven to be multibaggers in 2021-

Image description: YTD return of ACW, IMU, PTX, IHL, MXC

Source: ASX, as of 13 September 2021 (12:34 PM AEST)

RELATED ARTICLE: Five penny stocks that turned multibaggers this year

Actinogen Medical Limited (ASX:ACW)

ASX-listed biotechnology firm Actinogen Medical is engaged in the development of innovative therapies for neurological indications related to dysregulated brain cortisol. Currently, the Company is developing Xanamem™ as a new therapy for Fragile X syndrome, Alzheimer’s Disease and certain other potential neurological indications.

So far this year, the share price of ACW has risen from AU$0.021 to 0.094 (as of 13 September 2021).

Furthermore, the Company remains well-funded with a robust cash balance of AU$13.4 million as of 30 June 2021. Actinogen believes that this will be adequate to support all planned Phase 2 clinical trials.  

The three strategic priorities of Actinogen are-

Image Description: ACW strategic priorities

Source: ACW ASX Update, 30 August 2021

Imugene Ltd (ASX:IMU)*

ASX-listed biotechnology company Imugene is engaged in developing a comprehensive range of new therapies that attempt to activate the immune system of cancer patients for detecting and removing tumours. Backed by a leading team of international cancer experts, Imugene is working with the aim to improve and transform the lives of cancer patients who require effective treatments.

The share price of IMU has risen from AU$0.10 to AU$0.40 so far this year (as of 13 September 2021). In September rebalance, the Company was added to S&P/ASX 300 Index effective prior to the open on 20 September 2021.

RELATED ARTICLE: Imugene makes speedy progress in clinical trial activities in FY21

To know more about Imugene Click Here

Prescient Therapeutics Limited (ASX:PTX)*

Oncology player Prescient Therapeutics is working to harness innate adaptability and control of OmniCAR for developing next-generation CAR-T products for new and challenging tumors. The Company has licensed technologies and collaborated with world-leading cancer centres in the US.

In particular, the Company seeks to improve patient outcomes and offer innovative tools for clinicians facing difficulty to treat cancers.  

In this year, PTX share price raised from AU$0.067 to AU$0.220 as of 13 September 2021. Furthermore, PTX continues to develop its targeted therapies as well as cell therapies for the treatment of several hematological and solid cancers.

To know more about Prescient Therapeutics Click Here.

RELATED ARTICLE: Prescient (ASX:PTX) delivers a milestone-rich 2021, major strides made in OmniCAR development

Incannex Healthcare Limited (ASX:IHL)

Clinical stage pharmaceutical development firm Incannex Healthcare is developing unique medicinal cannabis therapies as well as psychedelic medicine therapies. In the financial year 2021, the Company has witnessed exciting research findings and rapid progress within its novel drug development program.

Furthermore, the Company has taken additional leaps in developing its unique cannabinoid-based and now psychedelic medicines for the indications with significant unmet patient needs. Incannex has expanded its partnerships with scientific experts and world-renowned academic institutions.  IHL plans to commence clinical trials for IHL-675A in South Australia in the fourth quarter of this year.

This year IHL share price has risen from AU$0.150 to AU$0.395 as of 13 September 2021.

RELATED ARTICLE: Three ASX-listed psychedelic medicine stocks to watch

MGC Pharmaceuticals (ASX:MXC)

European bio-pharma player MGC Pharmaceuticals is engaged in the development and supply of affordable standardised medicines derived from phytocannabinoid to patients all over the globe. In addition, the Company has entered into several research collaborations with world-renowned academic institutions.

In September 2021, the Company has obtained a grant to import CimetrA™ into India as a final stage for securing Emergency Use Authorisation (EUA) for the treatment of COVID-19. With the EUA, MGC Pharmaceuticals can market CimetrA™ as an approved COVID-19 treatment in India.

The share price of MXC has risen from AU$0.024 to AU$0.060 as of 13 September 2021.

RELATED ARTICLE: A look at four ASX-listed Cannabis stocks: MXC, AGH, AC8, BDA

*IMU and PTX are sponsored clients.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK